Podcast
#54: 2025 Diagnostic Trends and Innovations
Duration: 20 Minutes
Dec 17, 2025
Our 54th episode of QuidelOrtho Science Bytes features Jonathan Siegrist, PhD, Executive Vice President of Research & Development and Chief Technology Officer, exploring the breakthroughs shaping diagnostics in 2025.
From high-sensitivity troponin testing for faster cardiac care to non-invasive assays improving gastrointestinal health, rapid combo tests for respiratory surges and advances in molecular diagnostics, informatics and AI – these innovations are transforming workflows, guiding timely decisions and redefining patient care across the continuum.
Dr. Siegrist shares how cutting-edge research and next-generation platforms are driving smarter diagnostics – delivering fast, reliable insights that empower clinicians and improve outcomes worldwide.
This episode underscores a central theme: innovation isn’t just about technology – it’s about creating smarter, more connected systems that deliver better health, timely care and sustainable solutions for the future.
Disclaimers:
This educational podcast activity is brought to you by QuidelOrtho Corporation., and is not certified for continuing medical education. QuidelOrtho Corporation sponsors the program, and the speaker must present information following applicable FDA requirements.
This podcast includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ from those expressed in these statements. For full details, please review our complete disclaimer at the end of the transcript available for download above.
About our Speaker:
About our Speaker:
Jonathan Siegrist, PhD
Executive Vice President of Research & Development & Chief Technology Officer at QuidelOrtho
Jonathan is responsible for the company’s global R&D strategy, driving innovation and advancing next-generation diagnostic solutions. He brings over 15 years of leadership experience in the biotechnology and diagnostics industries, with a focus on molecular diagnostics, microfluidic platforms and biomedical engineering. Before joining QuidelOrtho, Jonathan served as Chief Technology Officer and head of assay research and development at Cepheid. Throughout his career, he has been recognized for his ability to lead complex, multidisciplinary teams while fostering a culture of creativity and innovation. Jonathan holds a PhD and Master of Science in biomedical engineering from the University of California, Irvine, and a Bachelor of Science in electrical engineering from the University of California, Los Angeles.
Jonathan is responsible for the company’s global R&D strategy, driving innovation and advancing next-generation diagnostic solutions. He brings over 15 years of leadership experience in the biotechnology and diagnostics industries, with a focus on molecular diagnostics, microfluidic platforms and biomedical engineering. Before joining QuidelOrtho, Jonathan served as Chief Technology Officer and head of assay research and development at Cepheid. Throughout his career, he has been recognized for his ability to lead complex, multidisciplinary teams while fostering a culture of creativity and innovation. Jonathan holds a PhD and Master of Science in biomedical engineering from the University of California, Irvine, and a Bachelor of Science in electrical engineering from the University of California, Los Angeles.
Key Takeaways:
- Faster cardiac care: High-sensitivity troponin testing accelerates diagnosis and treatment.
- Non-invasive solutions: New assays enhance gastrointestinal health without invasive procedures.
- Rapid response: Combo tests help clinicians manage respiratory surges efficiently.
- Next-gen diagnostics: Advances in molecular platforms, informatics and AI enable personalized care.
- Innovation at scale: R&D strategies are shaping diagnostics to meet global healthcare challenges.
